Stock comparison
IDEXX Laboratories
Royalty Pharma
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.06B
Sector
Healthcare
RPRX
Royalty Pharma
Market cap
$23.44B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | RPRX | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 66C | IDXX |
| Benjamin Graham | 80A | 84A | RPRX |
| Philip Fisher | 75B | 65C | IDXX |
| Peter Lynch | 71B | 60C | IDXX |
| Joel Greenblatt | 83C | 40D | IDXX |
| Charlie Munger | 87A | 68D | IDXX |
| Terry Smith | 84A | 58D | IDXX |
Side-by-side metrics
| Metric | IDXX | RPRX |
|---|---|---|
| Market cap | $44.06B | $23.44B |
| P/E (TTM) | 39.0x | 27.6x |
| EV/EBIT | 31.6x | 19.9x |
| ROIC (TTM) | 40.66% | 8.43% |
| Gross margin | 62.05% | 99.95% |
| Net margin | 24.63% | 33.91% |
| Revenue CAGR 5y | 7.56% | 0.96% |
| EPS CAGR 5y | 10.79% | 11.83% |
| Debt / Equity | 0.7x | 1.3x |
| Dividend yield | 0.0% | 1.72% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Revenue CAGR 5y7.56%vs 0.96%+87%
- ROIC (TTM)40.66%vs 8.43%+79%
- Market cap$44.06Bvs $23.44B+47%
- Debt / Equity0.7xvs 1.3x+47%
RPRX leads on
- Dividend yield1.72%vs 0.0%+100%
- Gross margin99.95%vs 62.05%+38%
- EV/EBIT19.9xvs 31.6x+37%
- P/E (TTM)27.6xvs 39.0x+29%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.